Next Article in Journal
Enhanced Efficacy of High Dose Oral Vancomycin Therapy in Clostridium difficile Diarrhea for Hospitalized Adults Not Responsive to Conventional Oral Vancomycin Therapy: Antibiotic Stewardship Implications
Next Article in Special Issue
Latest Innovations in the Treatment of Venous Disease
Previous Article in Journal
The Effect of Topical Ocular Anesthetic Proparacaine on Conjunctival and Nasal Mucosal Flora in Dry Eye Disease Patients
Previous Article in Special Issue
Safety, Efficacy and Evidence Base for Use of the Subcutaneous Implantable Cardioverter Defibrillator
Open AccessReview

Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma

1
Department of Cardiology, University of Connecticut School of Medicine, Farmington, CT 06030, USA
2
Hoffman Heart and Vascular Institute at St Francis Hospital and Medical Center, Hartford, CT 06105, USA
3
VACT Healthcare System, West Haven, CT 06516, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(4), 74; https://doi.org/10.3390/jcm7040074
Received: 14 March 2018 / Revised: 5 April 2018 / Accepted: 6 April 2018 / Published: 9 April 2018
(This article belongs to the Special Issue Advances in Interventional Cardiology and Vascular Medicine)
Percutaneous coronary intervention (PCI) with stenting for the treatment of acute coronary syndrome (ACS) is the contemporary standard of care. Such treatment is followed by dual antiplatelet therapy (DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. The decision regarding DAPT duration can be clinically challenging in the modern era with the evolution of newer stents, more potent antiplatelet agents, and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging “shared decision making”. The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy. View Full-Text
Keywords: dual antiplatelet therapy; coronary artery disease; acute coronary syndrome; drug eluting stent; bare metal stent; aspirin; clopidogrel; prasugrel; ticagrelor; triple therapy; oral anticoagulants dual antiplatelet therapy; coronary artery disease; acute coronary syndrome; drug eluting stent; bare metal stent; aspirin; clopidogrel; prasugrel; ticagrelor; triple therapy; oral anticoagulants
Show Figures

Figure 1

MDPI and ACS Style

Chaturvedula, S.; Diver, D.; Vashist, A. Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. J. Clin. Med. 2018, 7, 74.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop